Outlook Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended September 30, 2022. This is an annual report, not a standalone fourth-quarter report. Outlook Therapeutics is a pre-commercial biopharmaceutical company whose active development program is ONS-5010 (LYTENAVA, bevacizumab-vikg), an investigational ophthalmic treatment for retinal diseases.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Product sales revenue | None | None |
| Research and development expense | $42.3 million | $39.0 million |
| General and administrative expense | $20.7 million | $12.8 million |
| Operating loss | $63.1 million | $51.7 million |
| Net loss | $66.1 million | $53.2 million |
| Net loss per share | $0.31 | $0.35 |
| Cash used in operating activities | $56.7 million | $54.3 million |
| Cash and cash equivalents at year-end | $17.4 million | $14.5 million |
The filing reports no product-sales revenue; it does not provide a clear FY2022 collaboration-revenue figure in the supplied results. Gross margin is not meaningful because the company had no product sales. At September 30, 2022, total assets were $28.5 million, total liabilities $19.8 million, and stockholders’ equity $8.7 million. Current debt was $10.9 million net of loan costs; there was no long-term debt reported.
Changes versus prior year
- Net loss widened by $12.9 million, and operating loss widened by $11.3 million.
- R&D expense rose $3.4 million. Higher BLA submission fees and stock-based compensation were partly offset by lower ONS-5010 development costs after NORSE TWO and NORSE THREE were completed.
- G&A expense rose $8.0 million, reflecting higher compensation, professional fees tied to pre-launch preparations, insurance and other costs.
- Operating cash use increased $2.4 million. Financing activities provided $59.6 million, primarily from equity offerings and debt financing.
Outlook, risks and notable items
- The FDA accepted the resubmitted ONS-5010 BLA for filing, with an August 29, 2023 target date for a review decision. The company had voluntarily withdrawn its initial BLA in May 2022 to provide additional information requested by the FDA.
- The European MAA was validated for review in December 2022, with a decision expected in early 2024. U.S. launch plans for late 2023 and potential sales in calendar Q4 2023 depend on regulatory approval and financing.
- Management reported positive topline NORSE TWO results: 41.7% of ONS-5010 patients versus 23.1% of ranibizumab patients gained at least 15 BCVA letters in the primary dataset. These are reported trial results, not an approval or commercial outcome.
- The company expects its September 2022 cash plus post-year-end financing proceeds to fund operations into the third calendar quarter of 2023. Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern; additional capital will be needed.
- Post-year-end financing included a $24.0 million net equity offering and a convertible note with $31.8 million face value, 9.5% interest and a January 2024 maturity. The lender may convert beginning April 1, 2023, initially at $2.00 per share, subject to adjustment provisions. These transactions increased dilution and debt-related risk.
- Management expects to launch directly in the U.S. if approved and has a U.S. distribution and services arrangement with AmerisourceBergen. The company lacks an established sales organization and is considering partners for markets outside the U.S. It estimated a potential price of $500–$1,000 per dose.
- Key risks include dependence on ONS-5010, regulatory and manufacturing uncertainty, competition from approved anti-VEGF drugs and off-label compounded bevacizumab, reimbursement and pricing uncertainty, and the need for further financing. GMS Ventures and Tenshi held significant ownership stakes; GMS Ventures also has board-designation rights.
- The Liomont contract dispute was settled, with settlement payments completed and no remaining obligations reported. The auditor issued an unmodified opinion on the financial statements and highlighted going-concern uncertainty; management concluded disclosure controls and internal control over financial reporting were effective.
Investor verification priorities
- Track the FDA’s BLA review, any additional information requests or inspection findings, and the eventual decision; separately monitor the EMA review timetable.
- Reconcile the company’s cash runway, cash burn and financing needs against its stated Q3 2023 funding horizon, including the full terms and potential dilution from the convertible note.
- Assess whether manufacturing supply, distribution, sales capabilities and reimbursement arrangements are sufficient for a launch, if approved.
- Review final clinical and safety data, and the status and costs of planned additional-indication trials and the syringe study.
- Monitor share issuance, ownership concentration and any changes to major-stockholder rights or financing covenants.